Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem.

Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs.

Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Therapeutics

Life Sciences

Health Care

Biotechnology

Overland Pharmaceuticals

Ed Zhang

Wendy Yang

Sophie Chen

Eric H.

Yi-Shin Lai

Chia-Wei Chang

Weimin Li

Weijie Lan

Research and Development

Leadership Team

Teams at Overland Pharmaceuticals

Research and Development

Leadership Team